Axsome Therapeutics Provides Preliminary Fourth Quarter and

Preliminary total 4Q and full year 2023 net product revenue of $71 million and $204 million, respectively Auvelity preliminary 4Q and full year 2023 net product sales of $49 million and $130 million,...

Related Keywords

New York , United States , Japan , China , Darren Opland , Herriot Tabuteau , Mark Jacobson , Nasdaq , Corporate Communications , Sk Biopharmaceuticals Co Ltd , Us Drug Enforcement Agency On , Drug Administration , Development Pipeline Anticipated Milestones , World Trade Center , Axsome Therapeutics Inc , Chief Executive Officer , Fourth Quarter , Full Year , Product Revenue , Pipeline Anticipated , Trial Topline Results , Trial Initiations , Breakthrough Therapy , Prescribing Information , Boxed Warning , Enforcement Agency , Full Prescribing Information , Medication Guide , Axsome Therapeutics , Markets ,